Newsletter
Stay closely informed of our latest news.
Subscribe and stay closely informed of our latest news.
- 15/05/2026 – REIG JOFRE submits the conditions and report of the Scrip Dividend
- 08/05/2026 – REIG JOFRE submits the resolutions on 2026 General Shareholders’ Meeting
- 07/05/2026 – REIG JOFRE publishes its Q1 2026 financial results
- 01/04/2026 – REIG JOFRE convenes its Annual Shareholders’ Meeting 2026
- 03/03/2026 – SAVE THE DATE. 2025 Results and Outlook presentation
- 27/02/2026 – REIG JOFRE publishes its 2025 full year financial results
- 16/02/2026 – New website, same ambition
- 02/12/2025 – Reig Jofre acquires Leanbio and strengthens its vertical integration in biotechnology
- 05/11/2025 – Reig Jofre submits press release on the results for the third quarter of 2025
- 09/10/2025 – The European Commission visits Reig Jofre’s Barcelona plant
- 25/07/2025 – Reig Jofre submits report on financial results for the first half of 2025.
- 22/07/2025 – Independent analysis highlights Reig Jofre’s growth model
- 27/05/2025 – Bioglan Opens Cutting-Edge Facility
- 09/05/2025 – Reig Jofre news 8-9 May 2025
- 09/04/2025 – Reig Jofre submits the resolutions on 2025 General Shareholders’ Meeting
- 26/03/2025 – REIG JOFRE and LEO PHARMA join forces to improve access to an innovative psoriasis treatment in Primary Care
- 11/03/2025 – Results 2024 Presentation and Outlook 2025
- 07/03/2025 – Reig Jofre convenes its 2025 General Shareholders´ Meeting
- 28/02/2025 – Reig Jofre publishes its 2024 financial results
- 26/02/2025 – Reig Jofre strengthens its dermatology portfolio with the launch of Vincobiosis® Acneic for acne-prone skin
- 21/02/2025 – Save the Date: presentation of the 2024 financial results and 2025 outlook
- 15/01/2025 – Reig Jofre appoints Teresa Pérez de Prada as Director of its antibiotic development and production plant in Toledo
- 10/31/2024 – Reig Jofre submits submits press release on 2024 third quarter results
- 09/18/2024 – REIG JOFRE participates in a Consortium to validate and scale-up the human skin production generated by a 3D bioprinter
- 09/10/2024 – REIG JOFRE opens a subsidiary in Czech Republic
- 07/30/2024 – Reig Jofre submits press release on the results of the first half of 2024
- 07/01/2024 – Reig Jofre informs the liquidity contract with Solventis is extended until further notice
- 06/21/2024 – Reig Jofre informs about the start of trading of the new scrip dividend shares
- 06/18/2024 – REIG JOFRE joins the IBEX SMALL CAP INDEX
- 06/12/2024 – Reig Jofre informs on the bonus-shares capital increase
- 05/29/2024 – Reig Jofre participates as an Associate Partner in Med4Cure
- 05/28/2024 – Reig Jofre announces new analyst covering the stock
- 05/16/2024 – Reig Jofre informs on the execution of the Scrip Dividend
- 05/10/2024 – Reig Jofre submits press release on the results of the first quarter of 2024
- 04/19/2024 – Reig Jofre announces new analyst covering the stock
- 04/11/2024 – Reig Jofre submits the resolutions on 2024 General Shareholders\u2019 Meeting
- 04/08/2024 – Reig Jofre commits to vertical integration in the production of biotechnological medicines with an investment of eur 5.8m in Leanbio
- 03/08/2024 – Reig Jofre convenes its 2024 General Shareholders´ Meeting
- 03/06/2024 – Save The Date. Presentation Of 2023 Results And Future Outlook
- 02/29/2024 – Reig Jofre submits press release on the results of the fourth quarter of 2023
- 12/29/2023 – Our Best Wishes for the New Year 2024 | Reig Jofre
- 12/20/2023 – Appointment of the new Chief Financial Officer (CFO)
- 11/02/2023 – Reig Jofre reaches the milestone of 15 million vials of its intravenous anesthetic sold in Japan
- 10/30/2023 – Reig Jofre submits press release on the results of the third quarter of 2023
- 09/26/2023 – REIG JOFRE appointed Alex Sanfeliu as the new Global Head of Pharmaceutical Technologies business unit
- 07/27/2023 – Reig Jofre submits press release on the results of the second quarter of 2023
- 07/03/2023 – Extension the liquidity contract
- 06/30/2023 – Reig Jofre and Zendal appointed by the EU to ensure vaccine production capacity in Europe in case of future health emergencies
- 06/14/2023 – Reig Jofre informs on the start date of the trading of new shares of the Scrip Dividend
- 05/31/2023 – Ending of the process for the bonus-shares capital increase
- 05/04/2023 – Reig Jofre submits the schedule of the scrip dividend | Execution of the Scrip Dividend
- 04/28/2023 – Reig Jofre informs on the Scrip Dividend Conditions
- 04/11/2023 – 2023 General Shareholders’ Meeting Resolutions | Transactions within the liquidity contract
- 03/01/2023 – Reig Jofre convenes its 2023 General Shareholders Meeting
- 02/28/2023 – Reig Jofre submits results note on fourth quarter of 2022
- 12/13/2022 – Reig Jofre has successfully completed the co-development of TRIFERTY-ATM®, a food supplement that contributes to male fertility
- 11/02/2022 – REIG JOFRE submits press release on the global license agreement reached by Syna Therapeutics
- 10/28/2022 – Reig Jofre submits results note on third quarter of 2022
- 10/26/2022 – The Company announces the release date of its Q3 2022 results
- 09/07/2022 – FORTÉ PHARMA, REIG JOFRE’s brand of food supplements launches its E-commerce in China
- 07/26/2022 – Reig Jofre submits results note on second quarter of 2022
- 07/25/2022 – Reig Jofre informs on the start date of the trading of the new shares within its scrip dividend
- 07/12/2022 – Reig Jofre informs on the bonus-shares capital increase and the new shares to be issued for its scrip dividend
- 06/14/2022 – Execution of the scrip dividend
- 06/09/2022 – Reig Jofre informs on the Scrip Dividend Conditions
- 05/23/2022 – Reig Jofre launches Regenail® topical solution for structural nail alterations
- 04/29/2022 – Resolutions on 2022 General Shareholders´ Meeting
- 02/28/2022 – Reig Jofre submits results note on fourth quarter of 2021
- 11/15/2021 – Bioglan and Stada partner to increase capacity to meet rising demand for Parkinson´s treatment
- 10/29/2021 – Reig Jofre submits results note on third quarter of 2021
- 07/29/2021 – Reig Jofre submits results note on second quarter of 2021
- 07/22/2021 – Reig Jofre acquires 100% of REIG JOFRE UK LTD and consolidates its presence in the United Kingdom
- 07/21/2021 – Start of the trading of the new shares within its scrip dividend
- 07/06/2021 – Completion of liquidity contract | Increase in the bonus-share capital | Start of the second temporary share buyback program
- 06/09/2021 – Execution of the scrip dividend and conditions
- 05/11/2021 – Changes in the Board of Directors
- 04/29/2021 – Reig Jofre submits results note on the first quarter of 2021
- 04/26/2021 – Date change for release of the 1Q 2021 result note
- 04/20/2021 – Reig Jofre opens a subsidiary in Poland
- 03/26/2021 – Reig Jofre convenes its 2021 General Shareholders´ Meeting
- 02/26/2021 – Reig Jofre submits results note on the fourth quarter of 2020
- 12/15/2020 – Reig Jofre announces technology transfer of the large scale manufacturing in Spain for a Covid-19 vaccine candidate
- 11/13/2020 – Reig Jofre submits results note on the third quarter of 2020
- 10/23/2020 – Reig Jofre informs on the start date of the trading of the new shares within its scrip dividend
- 10/09/2020 – Distribution of a dividend in the form of scrip dividend
- 09/15/2020 – Execution of the scrip dividend
- 09/10/2020 – Conditions of the scrip dividend
- 07/23/2020 – Reig Jofre releases first half 2020 results note
- 07/16/2020 – Reig Jofre contributes its know-how in the development of biological vaccines to the innovative consortium of Vaxdyn
- 06/18/2020 – Reschedule of 1H 2020 results
- 06/17/2020 – Reig Jofre convenes its 2020 General Shareholders´ Meeting
- 05/13/2020 – Reig Jofre cierra el primer trimestre de 2020 con un crecimiento del 26% en ventas